Erythromycin 250 MG Delayed Release Oral Capsule — RxCUI 310154
RxNorm drug concept · Semantic clinical drug
RxCUI 310154
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI310154
Official nameErythromycin 250 MG Delayed Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)943 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Erythromycin Ophthalmic: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It's used to treat bacterial infections on the surface of your eye — the conjunctiva (the clear membrane over the white part) and the cornea (the clear front surface). It's also us...
- What exactly does this eye ointment treat?
- Gently pull your lower eyelid down to create a small pocket, then squeeze a ribbon of ointment — about 1 cm, roughly the size of a grain of rice — into that pocket. Blink a few tim...
- How do I apply the ointment without making a mess?
🕸️ Concept Web — How Erythromycin 250 MG Delayed Release Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Erythromycin 250 MG Delayed Release Oral Capsule
RxCUI 310154 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Erythromycin
4053IN
-
Erythromycin
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Erythromycin Delayed Release Oral Capsule
372070SCDF -
Erythromycin Oral Product
1164504SCDG -
Erythromycin Pill
1164505SCDG -
Delayed Release Oral Capsule
316995DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Erythromycin Delayed Release Oral Capsule
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Erythromycin 250 MG
317364SCDC
-
Erythromycin 250 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Erythromycin 250 MG
SCDC · 317364 -
Erythromycin Delayed Release Oral Capsule
SCDF · 372070 -
Erythromycin Oral Product
SCDG · 1164504 -
Erythromycin Pill
SCDG · 1164505
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 310154 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 24338-0120-13 | 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE (24338-120-13) | ERYTHROMYCIN | Arbor Pharmaceuticals, Inc. | 2012-01-10 |
| 75907-0076-01 | 100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (7... | erythromycin | Dr. Reddy's Labratories Inc. | 2024-09-01 |
Observed labelers:
Arbor Pharmaceuticals, Inc. (1) ·
Dr. Reddy's Labratories Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.